2CJP
Pharmaceutical compound
From Wikipedia, the free encyclopedia
2CJP, also known as 4-(4-bromo-2,5-dimethoxyphenyl)-2,3,4,5-tetrahydro-1H-2-benzazepine, is a serotonin receptor modulator of the phenethylamine, 2C, and N-benzylphenethylamine families.[1][2][3][4] It is a cyclized phenethylamine analogue of 25B-NBOMe in which the N-benzylethylamine side chain has been cyclized to form a tetrahydrobenzazepine ring.[1][2] The drug shows affinity for the serotonin 5-HT2A and 5-HT2C receptors (Ki = 19–457 nM and 227–3,240 nM, respectively).[3][4] 2CJP was first described in the scientific literature by Michael Robert Braden of the lab of David E. Nichols at Purdue University in 2007.[1][2]
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C18H20BrNO2 |
| Molar mass | 362.267 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
